ArticleBMC ophthalmology2019
Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
Article in BMC ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Histopathologic and ultrastructural features of the choriocapillaris in dogs with sudden acquired retinal degeneration syndrome and progressive retinal atrophy.Veterinary pathology · 2026Article
- Comparison of microvasculature between neovascular, non-neovascular chronic central serous chorioretinopathy cases and asymptomatic fellow eyes using swept-source optical coherence tomography angiography.International ophthalmology · 2025Article
- Predictive Factors for Morphological and Functional Improvements in Long-Lasting Central Serous Chorioretinopathy Treated with Photodynamic Therapy.Biomedicines · 2025Article
- Quantitative Changes in Vascular and Neural Fibers Induced by Subretinal Fluid Excluding the Peripapillary Region in Patients with Chronic Central Serous Chorioretinopathy.Diagnostics (Basel, Switzerland) · 2025Article
- Micropulse Laser Therapy in Central Serous Chorioretinopathy.Clinics and practice · 2024Article
- Quantification of Metamorphopsia in Resolved Idiopathic Central Serous Chorioretinopathy: An Analysis Using M-CHARTS, Amsler Grid, and Optical Coherence Tomography.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- The role of inflammation in central serous chorioretinopathy: From mechanisms to therapeutic prospects.Frontiers in pharmacology · 2024Review
- Biometric Risk Factors for Central Serous Chorioretinopathy.Ophthalmology and therapy · 2023Article
- Ganglion Cell Loss in the Course of Central Serous Chorioretinopathy.Ophthalmology and therapy · 2023Article
- Factors related to changes in visual symptoms after successful photodynamic therapy in central serous chorioretinopathy.PloS one · 2023Article
- Review
- Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses.International journal of retina and vitreous · 2022Article
- Significant Visual Impairment after Short-Lasting Central Serous Chorioretinopathy.Case reports in ophthalmology · 2022Article
- Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Safety of various parameter sets with navigated microsecond pulsing laser in central serous chorioretinopathy.International journal of retina and vitreous · 2021Article
- Imbalance in the Levels of Angiogenic Factors in Patients with Acute and Chronic Central Serous Chorioretinopathy.Journal of clinical medicine · 2021Article
- Choriocapillaris Ischemia at the Leakage Point of Patients With Acute Central Serous Chorioretinopathy.Frontiers in medicine · 2021Article
- Central Serous Chorioretinopathy Classification.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Short Term Presence of Subretinal Fluid in Central Serous Chorioretinopathy Affects Retinal Thickness and Function.Journal of clinical medicine · 2020Article
- Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy.Advances in ophthalmology practice and researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCentral serous chorioretinopathy (CSCR) is a complex ocular entity that, in its chronic form, can lead to serious visual impairment and morphological damage to the retina. The aim of the current retrospective study was to evaluate the damage present after long-standing but resolved central serous chorioretinopathy and refer it to healthy individuals. Correlations between measurable factors-for example, duration of the disease, baseline retinal morphological parameters, or patient age and/or their degree of impairment-were also assessed. MATERIALS AND
methodsThe study group consisted of thirty-two eyes (13 female and 19 male, mean age 49.6 years SD +/- 10.5) with chronic central serous chorioretinopathy (mean duration 18.9 months SD +/- 15.4) in which complete resolution of subretinal fluid was achieved after subthreshold micropulse laser treatment. Inclusion criterion was a lack of subretinal fluid within the whole area of the central retina scanned by the spectral domain optical coherence tomography. The group was extracted out of 51 cases of chronic CSCR that were treated with that method. They were analyzed according to final best-corrected visual acuity and retinal morphological parameters as measured by spectral optical coherence tomography with angiography option (OCTA). Results were compared with the outcomes of a control group, which consisted of 40 eyes of healthy individuals with full distance visual acuity (0.0 logMAR, 1.0 Snellen) never treated with subthreshold micropulse laser. Statistical analysis included regarding correlation between final visual acuity and final central retinal thickness and retinal and functional parameters prior to treatment.
resultsFinal best-corrected visual acuity after chronic central serous chorioretinopathy was 0.23 logMAR (0.6 Snellen) and central retinal thickness was 39.32 μm smaller than in controls. No correlation was found between final visual acuity and retinal thickness and duration of the disease, patient age, and baseline morphological retinal parameters. OCTA scans revealed impaired choriocapillaries flow signal even following resolution of the disease.
conclusionChronic central serous chorioretinopathy is a potentially damaging clinical entity that results in serious visual impairment, retinal thinning, and choroidal flow defects. Further research is needed to determine precisely the timepoint of this damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.